ITF already invests in Spanish: every community letter now has a Spanish version and the ARC brochure exists in Spanish. But duvyzat.com/es/ is one page, and its main buttons lead Spanish-speaking families into English: "MANTENERSE INFORMADO" opens the English sign-up form, "HISTORIAS REALES" opens the English stories page, and the page never mentions ITF ARC, the support program that offers translation, copay help and in-home lab monitoring. AGAMREE and ELEVIDYS both run Spanish versions.
First action
List every English link on /es/ and the Spanish assets that already exist.
How to measure it
Monthly sign-ups from /es/
- Now
- –
- Target
- Baseline, then +50%
- By
- 90 days
Steps
Inventory
English links on /es/ and existing Spanish assets (letters, brochures, PDFs).
Director, Duvyzat Patient Marketing 2 days
Translate the form
Spanish sign-up with a language field and the same consent wording.
Director, Duvyzat Patient Marketing 1 week
Add ITF ARC
A Spanish ARC section with the Spanish brochure and phone line.
Director, Duvyzat Patient Marketing 1 week
Subtitle the videos
Spanish subtitles for the Real Stories videos.
Director, Duvyzat Patient Marketing 2 weeks
MLR review
Route all translations as one submission.
Director, MLR Operations 2 weeks
Route follow-up
Spanish sign-ups flagged to ARC and the field team.
Patient services hub lead 1 week
Measure
Spanish sign-ups, ARC calls and starts from Spanish-speaking families.
Sr. Manager, Field Reporting & Analytics monthly
Why it works
Give the Spanish page its own path: a Spanish sign-up form (with a language field that also goes into the hub record), Spanish subtitles for the Real Stories videos, a Spanish ITF ARC section linking the existing Spanish brochure and the ARC phone line, and a Spanish advocacy-group list. Update the ™ to ® while it is in review. Then tag Spanish sign-ups so ARC and the field team can follow up in Spanish.
The content is already approved in English and partly translated, so this is mostly MLR review of translations, and it removes the point where a Spanish-speaking caregiver drops out: the form.
Ready to use
ChecklistSpanish path launch list
[ ] Spanish sign-up form with a language field [ ] "MANTENERSE INFORMADO" points to the Spanish form [ ] Spanish ITF ARC section and brochure link [ ] Spanish subtitles on the Real Stories videos [ ] Spanish advocacy-group list [ ] DUVYZAT(R) mark updated [ ] Spanish sign-ups tagged for ARC follow-up [ ] One MLR submission for all translations
Risks and how to handle them
Translation errors in medical wording
Use certified medical translators and MLR review.
Follow-up capacity in Spanish
Confirm ARC translation services before launch.
Evidence
- Brand websiteduvyzat.com/es/ is a single Spanish page whose menu items jump to sections of that page. Its "MANTENERSE INFORMADO" button opens the English sign-up form at /stay-informed/ (an English-language page), "HISTORIAS REALES" opens the English /real-stories/ page and the advocacy-group links open an English page. The Spanish page does not mention ITF ARC at all and still shows the old "DUVYZAT™" mark, while the English pages use "DUVYZAT®" (checked twice on October 23, 2026).Source
- Brand websiteITF ARC page: insurance navigation, prior authorization and appeal support, home delivery, "Personalized pharmacist guidance", "Translation services available as needed", in-home lab monitoring with a registered nurse, a copay program ("as little as $0 per month" for eligible commercially insured patients), a Patient Assistance Program and temporary supply programs. English and Spanish ARC brochures are linked from this English page only.Source
- Your websiteCommunity Letters: six letters from March 2024 to March 2026, each with a Spanish version (the Spanish versions were added on September 10, 2026), and a Spanish press release on U.S. commercial availability.Source
- Brand websitePatient sign-up form: first and last name, email, ZIP code, patient or caregiver or other, and "Currently on treatment with DUVYZAT? Yes / No", with consent to marketing and market research; there is no language choice.Source
- Competitor researchRivals' own sites: AGAMREE (vamorolone), "an FDA-approved corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older", links a Spanish site at /es/; the ELEVIDYS site declares a Spanish ("es") version; EMFLAZA (deflazacort): "Help extend his now with EMFLAZA".Source
- HiringDirector, Duvyzat Patient Marketing (posted October 15, 2026): engages "the individuals, caregivers, and families of those living with Duchenne muscular dystrophy", drives "adoption, compliance and persistence", oversees "media and digital strategy for both branded and non-branded", will "Lead and develop the patient ambassador program", use "social media" and "Interpret digital analytics", and "Collaborate with patient services HUB".Source